Efficacy of Selective RET Inhibitors in RET-Driven NSCLC and Thyroid Cancer: A Resource for Clinicians

Download this PDF resource for a quick overview of the efficacy data for pralsetinib and selpercatinib in RET fusion–positive NSCLC, RET fusion–positive thyroid cancer, and RET mutation–positive medullary thyroid cancer, along with a look at ongoing clinical trials.
Format: Adobe Acrobat (.pdf)
File Size: 87 KB
Released: January 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Phase I CHRYSALIS-2 updates: amivantamab + lazertinib in EGFRm NSCLC after progression with osimertinib and chemotherapy, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Adagrasib shows early encouraging activity in patients with KRAS G12C-mutant NSCLC and active, untreated CNS metastases, from Clinical Care Options (CCO) coverage of ASCO 2022

Released: June 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings